<DOC>
	<DOCNO>NCT00609401</DOCNO>
	<brief_summary>The ROSORC trial randomize study compare efficacy new association ( sorafenib IL-2 ) versus standard therapy ( sorafenib ) patient affect different histotypes metastatic RCC . This study first line therapy advance disease . The primary objective progression free survival ( PFS ) 2 arm therapy secondary objective overall survival ( OS ) response rate ( RR ) safety profile combination compare sorafenib alone .</brief_summary>
	<brief_title>Study Comparing Association Between Sorafenib Interleukin-2 ( IL-2 ) Versus Sorafenib 1st Line Therapy Advanced ( Adv ) Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description>Patients allocate 2 group : ARM A - Sorafenib 400 mg twice daily continuously low dose IL-2 administer s.c . ARM B - Sorafenib alone dosage use previous arm The trial stratify accord MSKCC prognostic model ( low intermediate high risk ) histology ( Clear cell v histotypes ) . The main inclusion criterion : cytohistological diagnosis RCC , measurable disease RECIST criterion , sign write informed consent , life expectancy great 3 month . The efficacy safety analysis perform intent treat population . The anticipated median PFS time control arm 6 month expect increase 3 month experimental arm . The sample size 128 patient , 64 arm ( 1:1 randomization ) The study start November 2006 multicenter Italian trial .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Cytohistological diagnosis RCC Written inform consent Measurable disease accord RECIST criterion Age &gt; = 18 year Karnofsky PS &gt; = 60 % Life expectancy great 3 month Prior medical treatment metastatic RCC Brain metastasis spinal cord compression Chronic treatment corticosteroid Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>RCC</keyword>
	<keyword>Metastatic disease</keyword>
</DOC>